NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE

一氧化氮、破骨细胞和代谢性骨疾病

基本信息

  • 批准号:
    6374990
  • 负责人:
  • 金额:
    $ 21.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-09-30 至 2005-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (Verbatim from the Applicant): Bone remodeling is a sensitively regulated dynamic process in which bone resorption by multinucleated osteoclasts (OCs) is normally closely followed by osteoblast (OB)-mediated bone formation. The multifunctional signal molecule, nitric oxide (NO), serves as an important intercellular autocrine and paracrine signal modulator in normal, as well as in pathological bone modeling and remodeling processes, and NO appears to exert profound effects on OB proliferation/survival, OC development and function. NO is formed from L-arginine in an oxidative reaction catalyzed by NO synthase (NOS) isoenzymes that are either constitutively expressed and calcium-activated (endothelial eNOS and neuronal nNOS isoforms), or transcriptionally induced (inducible NOS isoform) in response to inflammatory stimuli. Elevated NO levels potently inhibit bone resorption, both in vitro and in vivo, and NO actions on OCs, like other cells, involves a cGMP-dependent mechanism. The possible autocrine effect of NO on OCs has also begun to be examined, since it is now well established that OCs express both iNOS and eNOS. Although avian OCs express both iNOS messenger RNA (mRNA) and protein, inflammatory cytokines or LPS do not induce iNOS mRNA or protein in authentic mature Ocs, whereas elevated levels of calcium do. In contrast to Ocs, LPS and inflammatory cytokines induce iNOS and NO in many other cell types, including avian non-resorptive marrow-derived giant cells (MAGC). Therefore, we hypothesize that as OCs differentiate into fully functional resorption competent cells, the regulation of INOS expression is modified and this change in iNOS regulation impacts on OC-function in normal, as well as pathological OC function. The goal of this revised renewal application is to begin to understand the cell and molecular mechanisms involved in this unique OC iNOS regulation. The following Specific Aims are proposed: (1) to determine if the change in cytokine- and LPS-mediated OC iNOS regulation is a consequence of alterations in signaling pathways during the process of OC differentiation. As part of this aim, we will compare chicken, mouse, and human OC developmental models; (2) to identify promoter regulatory sequences and transcription factors that mediate (a) the differential induction of iNOS gene by calcium, PMA and inflammatory agents in MAGCs compared to mature resorbing OC, and (b) the inhibition of inflammatory-mediated iNOS gene induction following attachment of MAGCs to mineralized bone matrices; and (3) to analyze the signaling mechanisms by which NO alters OC activity. Such studies are anticipated to reveal new aspects of normal bone remodeling mechanisms and have potential to lend insight into skeletal pathologies such as implant loosening, osteoarthritis, other inflammatory skeletal disorders, and osteoporosis.
描述(来自申请人):骨重塑是一种敏感的

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Philip A Osdoby其他文献

Philip A Osdoby的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Philip A Osdoby', 18)}}的其他基金

OSTEOGENESIS IMPERFECTA, AND NITRIC OXIDE THERAPY
成骨不全和一氧化氮疗法
  • 批准号:
    7318366
  • 财政年份:
    2007
  • 资助金额:
    $ 21.71万
  • 项目类别:
OSTEOGENESIS IMPERFECTA, AND NITRIC OXIDE THERAPY
成骨不全和一氧化氮疗法
  • 批准号:
    7477733
  • 财政年份:
    2007
  • 资助金额:
    $ 21.71万
  • 项目类别:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
一氧化氮、破骨细胞和代谢性骨疾病
  • 批准号:
    6652038
  • 财政年份:
    2000
  • 资助金额:
    $ 21.71万
  • 项目类别:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
一氧化氮、破骨细胞和代谢性骨疾病
  • 批准号:
    6534426
  • 财政年份:
    2000
  • 资助金额:
    $ 21.71万
  • 项目类别:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
一氧化氮、破骨细胞和代谢性骨疾病
  • 批准号:
    6287613
  • 财政年份:
    2000
  • 资助金额:
    $ 21.71万
  • 项目类别:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
一氧化氮、破骨细胞和代谢性骨疾病
  • 批准号:
    6796894
  • 财政年份:
    2000
  • 资助金额:
    $ 21.71万
  • 项目类别:
OSTEOCLAST MEDIATED BONE REMODELING
破骨细胞介导的骨重塑
  • 批准号:
    6338643
  • 财政年份:
    2000
  • 资助金额:
    $ 21.71万
  • 项目类别:
OSTEOCLAST MEDIATED BONE REMODELING
破骨细胞介导的骨重塑
  • 批准号:
    6100405
  • 财政年份:
    1999
  • 资助金额:
    $ 21.71万
  • 项目类别:
CELLULAR BASIS OF CRANIOFACIAL BONE DISORDERS
颅面骨疾病的细胞基础
  • 批准号:
    6379723
  • 财政年份:
    1998
  • 资助金额:
    $ 21.71万
  • 项目类别:
CELLULAR BASIS OF CRANIOFACIAL BONE DISORDERS
颅面骨疾病的细胞基础
  • 批准号:
    6523818
  • 财政年份:
    1998
  • 资助金额:
    $ 21.71万
  • 项目类别:

相似海外基金

NOVEL RNASE PROTECTION ASSAY FOR CYTOKINE MRNAS
细胞因子 MRNAS 的新型 RNA 酶保护测定
  • 批准号:
    6317727
  • 财政年份:
    2000
  • 资助金额:
    $ 21.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了